2023-10-16 05:30:00 ET
Cathie Wood is known for buying tomorrow's potential success stories today, when their share prices may be in the doldrums and their products haven't yet reached the market -- or haven't reached their full potential. She gets in early at a great price, with the idea of reaping enormous rewards down the road. Wood's flagship Ark Innovation ETF has climbed by double digits this year, beating the S&P 500 .
Sometimes Wall Street agrees with Wood, and analysts expect a particular company's share price to surge from today's levels. That's the case for CRISPR Therapeutics (NASDAQ: CRSP) , a gene-editing company that Wood has been buying hand over fist. Wall Street predicts the gene-editing player's stock could climb 100% in the coming 12 months.
Are these predictions on target, or too optimistic? Let's find out.
For further details see:
This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street